Bioinformatics Drug Development Information 
Drug Target Review
JUNE 11, 2025
Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.
Drug Target Review
DECEMBER 6, 2024
Without this information, the interpretation of the dataset may be speculative or lead to inaccurate conclusions. For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JULY 11, 2025
Our mission as a company is to build the most impactful technologies that allow researchers and drug developers to understand underlying biology and ultimately use that to impact human health,” he says. I got my eyes opened to molecular biology, bioinformatics, computational biology and these emerging fields at the time.”
Drug Target Review
JULY 14, 2025
The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues. ” The consequences of these findings are severe, particularly for biotech companies.
Conversations in Drug Development Trends
APRIL 7, 2025
Furthermore, comprehensive genomic profiling in clinical trials generates real-world data that inform post-approval use and further refine treatment algorithms. In addition, biomarker integration provides real-time participant data that can help guide the trial course when using an adaptive trial design.
Drug Target Review
JULY 12, 2023
The clinical-stage oncology company develops medicines for broad populations of cancer patients and aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway, selectively impacting cancer cells while sparing healthy cells.
Drug Target Review
MAY 27, 2024
We feel that target discovery is the gatekeeper to successful drug development and can maximize our probability of success through diversified and thoughtful partnerships with biopharma. We are excited about our recently announced partnership with Merck KGaA, Darmstadt, Germany to discover and validate novel ADC targets.
Expert insights. Personalized for you.
65 
Let's personalize your content